Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibikase TherapeuticsIKT -2.62%35 3-1 Month Momentum % is 38.24% as of Aug. 28, 2026. GuruFocus rates IKT with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,389 Biotechnology companies, Inhibikase Therapeutics ranks better than 94.17% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-28), Inhibikase Therapeutics's 3-1 Month Momentum % is 38.24%.
The industry rank for Inhibikase Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
IKT's 3-1 Month Momentum % is ranked better than 94.17% of 1389
companies
in the Biotechnology industry
Industry Median: -8
vs IKT: 38.24
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Inhibikase Therapeutics 3-1 Month Momentum % Related Terms
IKT vs LXEO, XFOR, DMAC: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Inhibikase Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a 3-1 Month Momentum % of 38.24% as of Aug. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #81 out of 1389 companies in the Biotechnology industry, placing it in the top 5.8%.
Is Inhibikase Therapeutics' 3-1 Month Momentum % too high?
Inhibikase Therapeutics' current 3-1 Month Momentum % is 38.24%. Based on the distribution chart, Inhibikase Therapeutics ranks #81 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' 3-1 Month Momentum % compare to LXEO and XFOR?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #81 out of 1389 companies for 3-1 Month Momentum %. This places Inhibikase Therapeutics in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current 3-1 Month Momentum % is 38.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current 3-1 Month Momentum % of 38.24%. The current 3-1 Month Momentum % is 38.24%. Inhibikase Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current 3-1 Month Momentum % is 38.24% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
35GF Score
Get the complete analysis for IKT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
